Efficacy and Safety of Rituximab in Children with Refractory Nephrotic Syndrome; A Multicenter Clinical Trial

• Prif Awduron: Yo Han Ahn (Awdur), Hee Gyung Kang (Awdur), Seong Heon Kim (Awdur), Kyoung Hee Han (Awdur), Hee Yeon Cho (Awdur), Jae Il Shin (Awdur), Min Hyun Cho (Awdur), Young Seo Park (Awdur), Su Yung Kim (Awdur), Seung Joo Lee (Awdur), Hae Il Cheong (Awdur), Il-Soo Ha (Awdur)
• Fformat: Llyfr
• Cyhoeddwyd: The Korean Society of Nephrology, 2014-06-01T00:00:00Z.
• Pynciau: article
• Mynediad Ar-lein: Connect to this object online.

Rituximab (RTX), anti-CD20 monoclonal antibody, has been proposed as a rescue therapy for refractory nephrotic syndrome (NS) on the basis of favorable clinical observations. While reported efficacy of RTX on refractory RTX is promising, the long-term effect obtained from randomized clinical trial is...